Abstract
Malignant Hyperthermia(MH) is a hypermetabolic syndrome which is quite rare in India. Inhalational anesthetics and succinyl choline have been reported as potent triggering agents of MH. Dantrolene remains the gold standard for treating this life-threatening syndrome.
 We encountered a case of malignant hyperthermia in a 34-year-old male undergoing ventricular septal defect closure under general anesthesia. We successfully managed our patient by timely recognition of this syndrome and by administering prompt, effective symptomatic treatment and without dantrolene which was not available in our hospital. JMS 2018;21(1):40-43
Highlights
Malignant hyperthermia (MH) is a rare condition with very few case reports present in the literature
A positive family history of malignant hyperthermia in a first-degree relative is a strong indicator of MH susceptibility
As myoglobinemia due to excessive muscle destruction increases the risk of kidney injury, urine output should be maintained greater than 2 ml/kg/hr.[8]
Summary
Malignant hyperthermia (MH) is a rare condition with very few case reports present in the literature. We encountered a case of malignant hyperthermia in a 34 year old male undergoing ventricular septal defect closure under general anesthesia. About half an hour after induction, patients end tidal carbon dioxide (EtCO2) level increased from 40 mmHg to 57 mmHg while SpO2 remained stable.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
